Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 2/20 | 0.55 |
| ▸ | PLK1 | P53350 | 15/20 | 0.52 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 0.52 |
| ▸ | PLK2 | Q9NYY3 | 11/20 | 0.52 |
| ▸ | BRD4 | O60885 | 6/20 | 0.51 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.49 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | TAF1 | P21675 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828190 | 1.00 | MAPK7 (0.55) | MAPK7PLK1PLK3PLK2BRD4 | |
| SCHEMBL23828183 | 0.87 | PIP4K2A (0.64) | MAPK7PLK1PLK3PLK2BRD4 | |
| SCHEMBL23828184 | 0.87 | PIP4K2A (0.64) | MAPK7PLK1PLK3PLK2BRD4 | |
| SCHEMBL23828192 | 0.81 | PIP4K2A (0.74) | MAPK7PLK1PLK3PLK2BRD4 | |
| SCHEMBL23828191 | 0.81 | PIP4K2A (0.74) | MAPK7PLK1PLK3PLK2BRD4 | |
| SCHEMBL23849050 | 0.76 | PLK1 (0.51) | PLK1PLK3PLK2BRD4PIP4K2A | |
| SCHEMBL21683215 | 0.75 | PLK1 (0.50) | PLK1PLK3PLK2BRD4PIP4K2A | |
| SCHEMBL21683218 | 0.75 | PLK1 (0.50) | PLK1PLK3PLK2BRD4PIP4K2A | |
| SCHEMBL13551775 | 0.74 | PLK1 (0.82) | PLK1PLK3PLK2BRD4PARP1 | |
| SCHEMBL27369473 | 0.74 | PLK1 (0.82) | PLK1PLK3PLK2BRD4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773096-B2 | Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same | YALE UNIVERSITY (US) | 2023-10-03 | — | — | US | claimed |
| US-11773096-B2 | Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same | YALE UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210292326-A1 | Small-Molecule PI5P4K alpha/beta Inhibitors and Methods of Treatment Using Same | UNIV YALE (US) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773096-B2 | Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same | PI4KB, TP53, PI4K2B | MAPK7 1478/4885PLK1 140/4885PLK3 82/4885 |
| US-20210292326-A1 | Small-Molecule PI5P4K alpha/beta Inhibitors and Methods of Treatment Using Same | PI4KB, TP53, PI4K2B | MAPK7 1478/4885PLK1 140/4885PLK3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.